Balazs Halmos, MD, of Montefiore Albert Einstein Cancer Center, discussed the potential impact of subcutaneous amivantamab EGFR-mutated NSCLC.
Balazs Halmos, MD
Advertisement
Balazs Halmos, MD, oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center.
Articles by Balazs Halmos, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5
